BioCentury
ARTICLE | Clinical News

First look: Genentech vs. Merck in triple-negative

December 11, 2014 3:44 AM UTC

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) and Merck & Co. Inc. (NYSE:MRK) unveiled interim Phase I data for their targeted PD-1 compounds against triple-negative breast cancer (TNBC), with the former showing more robust overall response rates in patients previously treated with chemotherapy.

In a poster at the San Antonio Breast Cancer Symposium, Genentech reported 15 mg/kg or 20 mg/kg IV of its MPDL3280A every three weeks for up to 16 cycles showed an ORR of 33% in nine evaluable patients. One patient had complete response and two had partial reponses. ...